Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Gemphire Therapeutics Inc. (NASDAQ: GEMP).

Full DD Report for GEMP

You must become a subscriber to view this report.


Recent News from (NASDAQ: GEMP)

Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
LIVONIA, Mich., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), tod...
Source: GlobeNewswire
Date: December, 03 2018 08:00
NASH players under pressure following Liver Meeting abstract drop
Biotechs developing treatments for nonalcoholic steatohepatitis (NASH) and other fatty liver diseases are seeing some action following the release of abstracts for November's Liver Meeting in San Francisco. More news on: NGM Biopharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals...
Source: SeekingAlpha
Date: October, 02 2018 12:50
Tiziana Life Sciences Plans To Raise $16 Million In U.S. IPO
Quick Take Tiziana Life Sciences plc ( TLSA ) is seeking to raise $16 million in a U.S. IPO, according to an amended registration statement . The company is advancing a pipeline of therapeutic candidates for various cancers and immune diseases. TLSA is developing promising treatments ...
Source: SeekingAlpha
Date: September, 27 2018 13:16
Premarket Losers as of 9:05 am (9/7/2018)
ADXS   -30%  on announcing public offering of common stock and warrants. More news on: Advaxis Inc., MER Telemanagement Solutions Ltd., Ascent Capital Group, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 07 2018 09:10
Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer
SAN DIEGO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced that it has appointed Andrew Sassine as Interim Chief Financial Officer (CFO), effective August 24, 2018. Mr. Sassine has served on Arcturus’ Board...
Source: GlobeNewswire
Date: August, 28 2018 07:00
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Gemphire Therapeutics Inc.
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces it has commenced an investigation of Gemphire Therapeutics Inc. (“Gemphire” or “the Company”) (NASDAQ: GEMP) concerning possible violations of federal securities laws. On August 4, 2016...
Source: GlobeNewswire
Date: August, 21 2018 10:48
Midday Gainers / Losers (08/17/2018)
Gainers: TIK +56% . ZOES +34% . IZEA +28% . CNET +19% . CRMT +18% . YRD +15% . GEMP +13% . PPDF +13% . JWN +12% . ADRO +11% . Losers: ZN -27% . USEG -17% . BOXL -16% . ATGE -15% . DXR -14% . ATAC -14% . AMRS -13% . JMU -14% . ELO...
Source: SeekingAlpha
Date: August, 17 2018 12:45
Biotech Analysis Central Pharma News: Gemphire Pulls Plug, Ampio's FDA Despair, Paratek's Positive FDA Panel
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Gemphire Stops Study For treating Pediatric Patients With NASH News: This past Friday, shares of Gemphire Therapeutics ( GEMP ) fell by as much as 75...
Source: SeekingAlpha
Date: August, 13 2018 20:16
Gemphire Q2 cash at $28M
Gemphire Therapeutics (NASDAQ: GEMP ) Q2 highlights : More news on: Gemphire Therapeutics, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 13 2018 16:24
Gemphire Therapeutics beats by $0.08
Gemphire Therapeutics (NASDAQ: GEMP ): Q2 EPS of -$0.47 beats by $0.08 . More news on: Gemphire Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 13 2018 16:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-082.062.012.651.908,374,797
2018-05-176.416.376.505.95304,263
2017-09-0710.0210.0310.489.0848,759
2017-09-0610.6410.0410.649.8856,775
2017-09-059.6010.4710.509.2078,205

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1012,21723,37652.2630Short
2018-12-0712,89417,69072.8886Short
2018-12-0655,932111,54550.1430Short
2018-12-04133,961265,90450.3795Short
2018-12-0358,020103,26656.1850Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GEMP.


About Gemphire Therapeutics Inc. (NASDAQ: GEMP)

Logo for Gemphire Therapeutics Inc. (NASDAQ: GEMP)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $72,409,831 - 05/11/2018
  • Issue and Outstanding: 14,225,900 - 03/07/2018

 


Recent Filings from (NASDAQ: GEMP)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: GEMP)

Daily Technical Chart for (NASDAQ: GEMP)


Stay tuned for daily updates and more on (NASDAQ: GEMP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GEMP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GEMP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GEMP and does not buy, sell, or trade any shares of GEMP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/